THANK YOU FOR SUBSCRIBING
Pharma Tech Outlook | Sunday, August 19, 2018
Few months ago, the U.S. Food and Drug Administration approved the use of cannabidiol [CBD] oral solution for treating seizures in patients two years of age and older who are associated with two rare and severe forms of epilepsy—Lennox-Gastaut syndrome and Dravet syndrome. As a result, this has become the first FDA-approved medication containing drug substance derived from marijuana for treating Dravet syndrome affected patients. The extracted CBD, however, does not cause intoxication or euphoria that comes from tetrahydrocannabinol (THC).
This approval should work as a notice to assess the active components in marijuana for identifying important medical therapies. The most suitable way to bring marijuana-derived medications to the broad public is through controlled clinical trials testing the drug for safety and efficacy. It should also be followed by a careful review through the FDA’s drug approval process. Only because of the sufficient and well-controlled clinical studies that have supported this approval, prescribers can have trust in the drug’s uniform strength and regular delivery that support relevant dosing needed for treating patients with these complex and severe epilepsy syndromes. Organizations will continue to support systematic scientific research on the implied medical uses of marijuana-derived products and work with product developers who are engaged in delivering safe and effective, high-quality results. On a similar note, governments must stay prepared to take action when they see the illegal marketing of CBD-containing products with serious, unproven medical claims. Marketing unapproved products and random dosages and formulations can keep patients from accessing proper, recognized treatments to tackle serious and even fatal diseases. The difficult-to-control seizures faced by the patients have a profound impact on their quality of life. In addition to uncovering more treatment options, the cannabis-based drug can provide a meaningful and needed development in the therapeutic procedure of caring for the ailing people.
Stay ahead of the industry with exclusive feature stories on the top companies, expert insights and the latest news delivered straight to your inbox. Subscribe today.
The most severe risks include feelings of agitation, thoughts about suicide, attempts to commit suicide, new or worsening depression, and panic attacks—as is true for all drugs that are used in treating epilepsy. Some hard drugs have caused liver injury, generally mild, but raising the possibility of rare, but more severe complications. Severe liver injuries can cause nausea, vomiting, abdominal pain, fatigue, anorexia, jaundice, and dark urine. For making a scheduling judgment proposal, the FDA plans and delivers a medical and scientific analysis of substances to the Drug Enforcement Administration.
More in News